TRK inhibitor TQB3811

An orally bioavailable inhibitor of tropomyosin receptor kinase (TRK), with potential antineoplastic activity. Upon oral administration, TRK inhibitor TQB3811 targets and binds to TRK, thereby preventing neurotrophin-TRK interaction and TRK activation. This may lead to apoptosis of TRK-expressing tumor cells and the inhibition of tumor cell proliferation in TRK-expressing tumors. Members of TRK, a family of receptor tyrosine kinases activated by neurotrophins, are mutated in a variety of cancer cell types and play an important role in tumor cell growth and survival.